Haleon plc (HLN)vsTalphera Inc. (TLPH)
HLN
Haleon plc
$9.74
+0.41%
HEALTHCARE · Cap: $44.83B
TLPH
Talphera Inc.
$0.80
+9.08%
HEALTHCARE · Cap: $34.03M
Smart Verdict
WallStSmart Research — data-driven comparison
Haleon plc generates 39392757% more annual revenue ($11.03B vs $28,000). HLN leads profitability with a 15.1% profit margin vs 0.0%. HLN earns a higher WallStSmart Score of 58/100 (C).
HLN
Buy58
out of 100
Grade: C
TLPH
Avoid23
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+51.3%
Fair Value
$22.93
Current Price
$9.74
$13.19 discount
Intrinsic value data unavailable for TLPH.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 92.0% YoY
Strong operational efficiency at 23.2%
Generating 1.3B in free cash flow
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
0.6% revenue growth
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : HLN
The strongest argument for HLN centers on EPS Growth, Operating Margin, Free Cash Flow. Profitability is solid with margins at 15.1% and operating margin at 23.2%.
Bull Case : TLPH
The strongest argument for TLPH centers on Price/Book.
Bear Case : HLN
The primary concerns for HLN are PEG Ratio, Revenue Growth.
Bear Case : TLPH
The primary concerns for TLPH are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
TLPH carries more volatility with a beta of 0.49 — expect wider price swings.
HLN is growing revenue faster at 0.6% — sustainability is the question.
HLN generates stronger free cash flow (1.3B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.
Bottom Line
HLN scores higher overall (58/100 vs 23/100), backed by strong 15.1% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Haleon plc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Haleon plc (HLN) is a leading global consumer health company focused on delivering innovative health solutions across critical segments including oral care, pain relief, respiratory health, and dietary supplements. Formed from the spin-off of GlaxoSmithKline, Haleon boasts a strong portfolio of well-established brands, such as Sensodyne, Panadol, and Voltaren, solidifying its presence in the lucrative consumer health market. With a commitment to sustainability and consumer-driven innovation, the company is well-positioned to enhance health outcomes on a global scale while driving growth and delivering shareholder value through strategic investments and product advancements.
Visit Website →Talphera Inc.
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Talphera Inc. is a pioneering biotechnology firm specializing in the development of advanced therapies targeting rare diseases and significant unmet medical needs. The company leverages its expertise in peptide-based therapeutics to address critical challenges in cancer treatment and other high-need health areas. With a robust pipeline of innovative therapeutic candidates and a strong dedication to research excellence, Talphera is well-positioned for transformative contributions to the healthcare sector. For institutional investors, Talphera represents a compelling opportunity to engage with a growth-oriented company in the expanding biotechnology landscape.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?